Psychedelic Bulletin 214 covers a collapsed LSD microdosing program, a Phase 2b debrief for Atai Beckley, and UK policy responses on psilocybin questions

LSD microdosing programs can collapse, and Psychedelicalpha tracks what that failure means for early adoption claims. The bulletin also shares a debrief of Atai Beckley’s Phase 2b work, focusing on what was learned from the trial and what it implies for next development steps. Finally, the UK government response to MPs’ psilocybin related questions is summarized, tying clinical progress and public debate to concrete policy and regulatory signals.